Combining Esketamine and Prolonged Exposure for PTSD: A Proof-of-Concept Clinical Trial
This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food & Drug Administration (FDA) for treatment resistant depression. Combined with PE, intranasal ketamine may help to augment PE and further reduce participants' PTSD symptoms.
- Status
- completed
- Phase
- Phase 1, Phase 2
- Institution
- The University of Texas Health Science Center at San Antonio
- Principal investigator
- Casey Straud, PsyD
- Start date
- 2025-06-09
- End date
- 2026-01-16
- Registry ID
- NCT06795659
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.